<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647049</url>
  </required_header>
  <id_info>
    <org_study_id>ZNS-00465</org_study_id>
    <nct_id>NCT00647049</nct_id>
  </id_info>
  <brief_title>Freiburg ZNS-NHL Study</brief_title>
  <official_title>Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether combined chemotherapy [rituximab plus high
      dosage methotrexate (max. 2 cycles) followed by arabinoside/thiotepa (max. 2 cycles) followed
      by high dosage carmustin/thiotepa] followed by peripheral blood stem cell transplantation is
      effective in the treatment of cerebral Non Hodgkin lymphoma [PCNSL].
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>30 days after blood stem cell transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological state according to Mini-Mental State</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological assessment (digit span, Hopkins verbal Learning Test-Revised, Trials 1-3, Brief Test of Attention, Trial Making Test, Grooved Pegboard, 6. HVLT-R , EORTC L C30 , EORTC BN20)</measure>
    <time_frame>within 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Serious) adverse events ([S]AEs)</measure>
    <time_frame>within 30 days after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Primary Non Hodgkin Lymphoma of the Central Nervous System</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first diagnosis of PCNSL: combined chemotherapy with methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapse or progressive disease of PCNSL after methotrexate containing chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>8000mg/m2 i.v., max. 2 cycles</description>
    <arm_group_label>A</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2, max. 8 times</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>3000mg/m2 die i.v., 2 days (max. 2 cycles)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustin</intervention_name>
    <description>400mg/m2 i.v. for 1 day</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Bis-Chlorethyl-Nitrosourea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  group A: first diagnosis of PCNSL, histologically confirmed

          -  group B: relapse or progression of PCNSL after MTX containing chemotherapy

          -  age 18 - 65 years

          -  not legally incompetent, physically or mentally incapable of giving consent

          -  written signed and dated informed consent of the legal representative and - if
             possible - of the patient

        Exclusion Criteria:

          -  manifestations of further lymphoma outside the CNS

          -  sero-positive for HIV

          -  severe pulmonary, cardiac, hepatic, renal impairment

          -  neutrophil count &lt; 2.000/µl, platelet count &lt; 100.000/µl

          -  pulmonary disease with IVC &lt; 55%, DLCO &lt; 40%

          -  cardiac ejection fraction &lt; 50%, uncontrolled malign arrhythmia

          -  creatinine &gt; 1,5 mg% or creatinine-clearance &lt; 50ml/min

          -  bilirubin &gt; 2mg/dl

          -  ascites or pleural effusion (&gt; 500ml)

          -  pregnancy o r lactation

          -  women with childbearing potential without sufficient contraception

          -  participation in another clinical trial within the last 30 days prior to the begin or
             parallel to this study

          -  known or current drug or alcohol abuse

          -  known hypersensitivity against methotrexate, cytarabine, thiotepa, BCNU rituximab,
             leukovorin, dexamethasone, neupogen and neulasta.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Finke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerald Illerhaus, Dr.</last_name>
    <phone>00497612703785</phone>
    <email>Gerald.Illerhaus@uniklinik-freiburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Zähringer, Dr.</last_name>
    <phone>00497612707370</phone>
    <email>andreas.zaehringer@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Illerhaus, Dr.</last_name>
      <phone>00497612703785</phone>
      <email>Gerald.Illerhaus@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Zähringer</last_name>
      <phone>00497612707378</phone>
      <email>andreas.zaehringer@uniklinik-freiburg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24.</citation>
    <PMID>16864853</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>November 16, 2009</last_update_submitted>
  <last_update_submitted_qc>November 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. G. Illerhaus</name_title>
    <organization>University Hospital Freiburg</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

